MicroPort Scientific Corporation Share Price

Equities

853

KYG608371046

Advanced Medical Equipment & Technology

Market Closed - Hong Kong S.E. 09:08:20 26/04/2024 BST 5-day change 1st Jan Change
5.9 HKD +3.51% Intraday chart for MicroPort Scientific Corporation +11.11% -29.93%

Financials

Sales 2023 951M 7.44B 76.11B Sales 2024 * 1.19B 9.31B 95.21B Capitalization 1.38B 10.81B 111B
Net income 2023 -478M -3.74B -38.27B Net income 2024 * -211M -1.65B -16.89B EV / Sales 2023 2.08 x
Net Debt 2023 * 186M 1.45B 14.85B Net Debt 2024 * 209M 1.64B 16.73B EV / Sales 2024 * 1.34 x
P/E ratio 2023
-4.12 x
P/E ratio 2024 *
-6.22 x
Employees 8,230
Yield 2023 *
0.27%
Yield 2024 *
-
Free-Float 50.4%
More Fundamentals * Assessed data
Dynamic Chart
Nomura Adjusts MicroPort Scientific’s Price Target to HK$6.71 From HK$7.19, Keeps at Neutral MT
MicroPort Scientific to Receive $150 Million Loan Facility, $300 Million Credit Support to Repay Convertible Bonds MT
MicroPort Scientific Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Nomura Adjusts MicroPort Scientific’s Price Target to HK$7.19 From HK$17.59, Keeps at Neutral MT
MicroPort Scientific Corporation Provides Earnings Guidance for the Year Ended 31 December 2023 CI
MicroPort Scientific Corporation Reports Revenue Results for the Twelve Months Ended 31 December 2023 CI
MicroPort Scientific Unit to See Up to 38% Boost in 2023 Profit MT
MicroPort Scientific Raises $220 Million from Convertible Bond Issue; To Buy Back, Cancel $217 Million of Existing Bonds MT
Otsuka's Unit Remains as MicroPort Scientific's Thai Distributor Until 2026 MT
EV MedTech Raises 1.8 Billion Yuan from Placement MT
MicroPort Scientific Says Businesses Maintain Steady Growth MT
MicroPort Launches Tender Offer for Zero-Coupon Bonds Due 2026; To Issue New Debts Worth $220 Million MT
MicroPort Scientific Names Dealer Managers for $700 Million Convertible Bond Buyback; Shares Plunge 19% MT
Microport Neurotech Limited and Microport Scientific Corporation Agrees to Renew the 2022 Master Materials Procurement Agreement, the 2022 Master Supporting Services Procurement Agreement and the 2022 Master Catering Services Agreement CI
MicroPort Scientific Corporation Announces Appointment of Peng Bo as Non-Executive Director and Member of the Strategic Committee CI
More news
1 day+3.51%
1 week+11.11%
Current month-10.20%
1 month-7.96%
3 months-3.75%
6 months-42.61%
Current year-29.93%
More quotes
1 week
5.23
Extreme 5.23
5.92
1 month
5.23
Extreme 5.23
7.15
Current year
5.23
Extreme 5.23
8.52
1 year
5.23
Extreme 5.23
18.36
3 years
5.23
Extreme 5.23
72.85
5 years
5.21
Extreme 5.21
72.85
10 years
2.63
Extreme 2.63
72.85
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 30/04/98
Director of Finance/CFO 48 21/07/10
Chief Operating Officer 67 31/12/16
Members of the board TitleAgeSince
Director/Board Member 70 31/10/06
Director/Board Member 60 02/09/10
Chief Executive Officer 61 30/04/98
More insiders
Date Price Change Volume
26/04/24 5.9 +3.51% 12,059,590
25/04/24 5.7 -1.38% 5,902,795
24/04/24 5.78 +3.03% 4,695,530
23/04/24 5.61 +3.89% 6,462,353
22/04/24 5.4 +1.69% 4,992,106

Delayed Quote Hong Kong S.E., April 26, 2024 at 09:08 am

More quotes
MicroPort Scientific Corporation is a Hong Kong-based investment holding company principally engaged in the manufacture and sales of medical products. The Company operates through seven segments. Orthopedics Devices segment researches, develops, manufactures and sells orthopedics devices. Cardiovascular Devices segment researches, develops, manufactures and sells cardiovascular devices, such as drug eluting stents. Endovascular Devices segment researches, develops, manufactures and sells endovascular devices. Electrophysiology Devices segment researches, develops, manufactures and sells electrophysiology devices. Neurovascular Devices segment researches, develops, manufactures and sells neurovascular devices. Surgical Management segment researches, develops, manufactures and sells surgical devices. Diabetes Care and Endocrinal Management segment researches, develops, manufactures and sells devices related to diabetes mellitus.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
0.7537 USD
Average target price
1.703 USD
Spread / Average Target
+125.96%
Consensus

Annual profits - Rate of surprise